Very early molecular marker of tumor response to PD-1 inhibition in plasma of patients with advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Hiltermann, Thijo Jeroen Nicolaas
Miedema, A.
Hijmering-Kappelle, Lucie
Groen, Harry J. M.
Schuuring, Ed
机构：
[1] Univ Med Ctr Groningen, Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3030
引用
收藏
页数：5
相关论文
共 50 条
  • [11] Evaluation of PD-1 and PD-L1 expression on CTCs isolated from non-small cell lung cancer (NSCLC) tumor patients
    Kallergi, G.
    Aggouraki, D.
    Katsarlinos, P.
    Vetsika, E. K.
    Lagoudaki, E.
    Koinis, F.
    Koutsopoulos, A.
    Georgoulias, V.
    Kotsakis, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [12] Interleukin 8 in plasma is an efficacy marker for advanced non-small cell lung cancer treated with hypofractionated radiotherapy and PD-1 blockade
    Kang, Pengyuan
    Liu, Dan
    Li, Lin
    Guo, Xiyuan
    Ye, Yingchun
    Li, Yunfei
    Jiang, Qin
    Lin, Sheng
    Yuan, Qing
    CYTOKINE, 2023, 163
  • [13] Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome
    Nishino, Mizuki
    Dahlberg, Suzanne E.
    Adeni, Anika E.
    Lydon, Christine A.
    Hatabu, Hiroto
    Janne, Pasi A.
    Hodi, F. Stephen
    Awad, Mark M.
    CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5737 - 5744
  • [14] Safety and clinical efficacy of programmed cell death 1 antibodies (PD-1 Ab) in patients with advanced non-small cell lung cancer (NSCLC).
    Ksienski, Doran
    Wai, Elaine
    Croteau, Nicole
    Lesperance, Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)
  • [15] A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
    Mohammad Jafarnejad
    Chang Gong
    Edward Gabrielson
    Imke H. Bartelink
    Paolo Vicini
    Bing Wang
    Rajesh Narwal
    Lorin Roskos
    Aleksander S. Popel
    The AAPS Journal, 21
  • [16] A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
    Jafarnejad, Mohammad
    Gong, Chang
    Gabrielson, Edward
    Bartelink, Imke H.
    Vicini, Paolo
    Wang, Bing
    Narwal, Rajesh
    Roskos, Lorin
    Popel, Aleksander S.
    AAPS JOURNAL, 2019, 21 (05):
  • [17] Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
    Zhang, Xi
    Chen, Rui
    Huo, Zirong
    Li, Wenqing
    Jiang, Mengju
    Su, Guodong
    Liu, Yuru
    Cai, Yu
    Huang, Wuhao
    Xiong, Yuyan
    Wang, Shengguang
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [18] Efficacy and safety of the PD-1/PD-L1 in metastasic non-small cell lung cancer (NSCLC)
    Gonzalez-Velez, Abel
    Pino-Villareal, Luis E.
    Barrera-Barinas, Alexander
    Castillo-Niuman, Andrea
    Tolosa-Perez, Erica N.
    Castelblanco, Diana, I
    Pinzon-Florez, Carlos E.
    Yomayusa, Nancy
    GACETA MEXICANA DE ONCOLOGIA, 2021, 20 (03): : 111 - 123
  • [19] Molecular marker expression in non-small cell lung cancer (NSCLC) in Humberside
    Roejkjaer, Eline
    Saleem, Azeem
    LUNG CANCER, 2024, 190
  • [20] Early Clinical Predictors of Progressive Disease or Non-Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
    Kumar, R.
    Brandao, M.
    Joharatnam, N.
    Pealing, J.
    Walder, D.
    Minchom, A.
    Milner-Watts, C.
    Moorcraft, S. Y.
    Turkes, F.
    Yousaf, N.
    Bhosle, J.
    Popat, S.
    O'Brien, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2147 - S2147
12345